Kaleido Biosciences (Kaleido Biosciences) EBIT : $-87.45 Mil (TTM As of Dec. 2021)

View and export this data going back to 2019. Start your Free Trial

What is Kaleido Biosciences EBIT?

Kaleido Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2021 was $-19.56 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2021 was $-87.45 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kaleido Biosciences's annualized ROC % for the quarter that ended in Dec. 2021 was -378.16%. Kaleido Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was -1,203.14%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kaleido Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was 521.28%.

Kaleido Biosciences EBIT Historical Data

The historical data trend for Kaleido Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaleido Biosciences EBIT Chart

Kaleido Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT

Get a 7-Day Free Trial

-27.12

-60.74

-85.35

-78.82

-87.45

Kaleido Biosciences Quarterly Data
	Dec16	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
EBIT	Get a 7-Day Free Trial														-19.30	-22.33	-23.18	-22.38	-19.56

Competitive Comparison of Kaleido Biosciences's EBIT

For the Biotechnology subindustry, Kaleido Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kaleido Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kaleido Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kaleido Biosciences's EV-to-EBIT falls into.

Kaleido Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-87.45 Mil.

Kaleido Biosciences (OTCPK:KLDO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kaleido Biosciences's annualized ROC % for the quarter that ended in Dec. 2021 is calculated as:

	ROC % (Q: Dec. 2021 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2021 )	+	Invested Capital (Q: Dec. 2021 ))	/ count )
=	-78.796 * ( 1 - 0% )	/	( (16.521	+	25.152)	/ 2 )
=	-78.796	/	20.8365
=	-378.16 %

where

	Invested Capital		(Q: Sep. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	67.804	-	12.24	-	( 55.657	-	max(0, 19.261	-	58.304	+	55.657	))
=	16.521

	Invested Capital		(Q: Dec. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	50.137	-	12.356	-	( 38.474	-	max(0, 29.682	-	42.311	+	38.474	))
=	25.152

Note: The Operating Income data used here is four times the quarterly (Dec. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Kaleido Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2021 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2021		Q: Dec. 2021
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-78.228	/	( ( (7.339 + max(-10.23, 0))	+	(5.665 + max(-9.701, 0)) )	/	2 )
=	-78.228	/	( ( 7.339	+	5.665 )	/	2 )
=	-78.228	/	6.502
=	-1,203.14 %

where Working Capital is:

	Working Capital		(Q: Sep. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.647)	-	(12.24	+	0.15	+	0.487)
=	-10.23

	Working Capital		(Q: Dec. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.837)	-	(12.356	+	0.828	+	0.354)
=	-9.701

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2021) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kaleido Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2021 )
	=	-87.45	/	-16.776
	=	521.28 %

Kaleido Biosciences EBIT Related Terms

Thank you for viewing the detailed overview of Kaleido Biosciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Kaleido Biosciences (Kaleido Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kaleido Biosciences Inc (OTCPK:KLDO) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Hayden Avenue, Lexington, MA, USA, 02421

Website

http://www.kaleido.com

Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.

Executives

Alison S Long	officer: Chief Medical Officer	KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Van Hylckama Vlieg Johan	officer: Chief Scientific Officer	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Flagship Ventures Fund Iv, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Daniel L Menichella	director, officer: Chief Executive Officer	79 TW ALEXANDER DRIVE, 4101 RESEARCH COMMONS, RESEARCH TRIANGLE PARK NC 27709
Kyriazi Theo Melas	director	2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
Nutritional Health Ltp Fund General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Nutritional Health Ltp Fund, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Anne Prener	director	C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
William E. Duke	officer: CHIEF FINANCIAL OFFICER	C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Richard William Scalzo	officer: Principal Accounting Officer	25 ALBERTA LANE, HOLLISTON MA 01746
Jean K Mixer	director	C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Jerald Korn	officer: General Counsel	128 GORDON RD, NEWTON MA 02468
Flagship Ventures Fund V, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Michael W Bonney	director, officer: Executive Chair	65 HAYDEN AVE, LEXINGTON MA 02421
Flagship Venturelabs V Manager Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142